Giuseppe Orefice

Giuseppe Orefice

Auto-generated profile, based on publicly available information

Giuseppe Orefice

Federico II University

Research Focus & Metrics

Academic Career Length

46Years (1981-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RERoberto Erro
Roberto Erro
CVCarmine Vitale
Carmine Vitale
MAMarianna Amboni
Marianna Amboni
Marina PicilloMarina Picillo
Marina Picillo
Marcello MocciaMarcello Moccia
Marcello Moccia
PBPaolo Barone
Paolo Barone
The variability in the clinical phenotype of Parkinson’s disease seems to suggest the existence of several subtypes of the disease. To test this hypothesis we performed a cluster analysis using data assessing both motor and non-motor symptoms in a large cohort of newly diagnosed untreated PD patients. We collected data on demographic, motor, and the whole complex of non-motor symptoms from 100 consecutive newly diagnosed untreated outpatients. Statistical cluster analysis allowed the identification of different subgroups, which have been subsequently explored. The data driven approach identified four distinct groups of patients, we have labeled: 1) Benign Pure Motor; 2) Benign mixed Motor-Non-Motor; 3) Non-Motor Dominant; and 4) Motor Dominant. Our results confirmed the existence of different subgroups of early PD patients. Cluster analysis revealed the presence of distinct subtypes of patients profiled according to the relevance of both motor and non-motor symptoms. Identification of such subtypes may have important implications for generating pathogenetic hypotheses and therapeutic strategies.

1 February 2006 in NeuroImage
Verified
Journal Article
Closed access
APAnna Prinster
Anna Prinster
Mario QuarantelliMario Quarantelli
Mario Quarantelli
GOG. Orefice
G. Orefice
RLRoberta Lanzillo
Roberta Lanzillo
ABArturo Brunetti
Arturo Brunetti
MSMarco Salvatore
Marco Salvatore

26 July 2005 in Neurology
Verified
Journal Article
Closed access
PDF file
GTG. Tedeschi
G. Tedeschi
LLL. Lavorgna
L. Lavorgna
GPGiorgio Palù
Giorgio Palù
APA. Prinster
A. Prinster
DDD. Dinacci
D. Dinacci
BAB. Alfano
B. Alfano
Objective: To measure white matter (WM) and gray matter (GM) atrophy and lesion load in a large population of patients with multiple sclerosis (MS) using a fully automated, operator-independent, multiparametric segmentation method. Methods: The study population consisted of 597 patients with MS and 104 control subjects. The MRI parameters were abnormal WM fraction (AWM-f), global WM-f (gWM-f), and GM fraction (GM-f). Results: Significant differences between patients with MS and control subjects included higher AWM-f and reduced gWM-f and GM-f. MRI data showed significant differences between patients with relapsing-remitting and secondary progressive forms of MS. Significant correlations between MRI parameters and between MRI and clinical data were found. Conclusions: Patients with multiple sclerosis have significant atrophy of both white matter (WM) and gray matter (GM); secondary progressive patients have significantly more atrophy of both WM and GM than do relapsing-remitting patients and a significantly higher lesion load (abnormal WM fraction); lesion load is related to both WM and even more to GM atrophy; lesion load and WM and GM atrophy are significantly related to Expanded Disability Status Scale score and age at onset (suggesting that the younger the age at disease onset, the worse the lesion load and brain atrophy); and GM atrophy is the most significant MRI variable in determining the final disability.

1 December 2007 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
GTGioacchino Tedeschi
Gioacchino Tedeschi
DDDaria Dinacci
Daria Dinacci
LLluigi lavorgna
luigi lavorgna
APAnna Prinster
Anna Prinster
GSGiovanni Savettieri
Giovanni Savettieri
BABruno Alfano
Bruno Alfano

1 August 2002 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Open access
PDF file
ABAntonio Bertolotto
Antonio Bertolotto
SMS Malucchi
S Malucchi
ASA Sala
A Sala
GOG Orefice
G Orefice
PCP B Carrieri
P B Carrieri
MGM T Giordana
M T Giordana
Objective: To evaluate the incidence and the prevalence of neutralising antibodies (NABs) to three interferon beta (IFNβ) products in patients with multiple sclerosis (MS). Methods: Sera were tested from 125 patients with relapsing-remitting MS. Patients were treated with IFNβ-1b (Betaferon, n = 29) 8 MIU subcutaneously every other day, IFNβ-1a (Avonex, n = 44) 30 μg intramuscularly once weekly, or IFNβ-1a (Rebif, n = 36) 22 μg subcutaneously three times weekly for 6 to 18 months. An additional 16 patients were treated with Rebif 22 μg intramuscularly once or twice weekly. NABs were assessed using the cytopathic effect assay before treatment and every three months during treatment. Patients with two or more consecutive positive samples were considered to be persistent NAB positive (NAB+). Results: At baseline, no patients were NAB+. NABs developed during the first three months of treatment and continued to develop until month 18. Over 18 months of treatment, the risk of being persistent NAB+ was 31% for Betaferon, 15% for Rebif, and 2% for Avonex (Betaferon versus Avonex, p = 0.001; Betaferon versus Rebif, p = 0.19; Rebif versus Avonex, p = 0.04). In all patients with one or more NAB+ samples, the risk of becoming NAB+ was 38% for Betaferon, 18% for Rebif, and 7% for Avonex (Betaferon versus Avonex, p = 0.0007; Betaferon versus Rebif, p = 0.10; Rebif versus Avonex, p = 0.07). At month 18, the prevalence of persistent NAB+ patients was 31.6% for Betaferon, 18.7% for Rebif, and 4% for Avonex. Numbers of NAB+ patients observed were similar with intramuscular Rebif and with subcutaneous Rebif. Conclusion: The three IFNβ preparations have different degrees of immunogenicity, with Betaferon producing the highest incidence of NABs and Avonex the lowest. These differences should be considered by neurologists when selecting treatment for their patients with MS because NABs can reduce both bioavailability and clinical efficacy of IFNβ.

30 August 2013 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
Marina PicilloMarina Picillo
Marina Picillo
MAMarianna Amboni
Marianna Amboni
RERoberto Erro
Roberto Erro
KLKatia Longo
Katia Longo
CVCarmine Vitale
Carmine Vitale
MPMaria Teresa Pellecchia
Maria Teresa Pellecchia